Biological barriers are essential physiological protective systems and obstacles to drug
delivery. Nanoparticles (NPs) can access the paracellular route of biological barriers, either …

Nanoparticles as drug delivery carriers have benefited diseases, including cancer, since the
1990s, and more recently, their promise to quickly and efficiently be mobilized to fight …

Treating pregnancy-related disorders is exceptionally challenging because the threat of
maternal and/or fetal toxicity discourages the use of existing medications and hinders new …

During healthy pregnancy, the placenta develops to allow for exchange of nutrients and
oxygen between the mother and the fetus. However, placental dysregulation can lead to …

Congenital disorders resulting in pathological protein deficiencies are most often treated
postnatally with protein or enzyme replacement therapies. However, treatment of these …

The treatment of women's health-related conditions, including reproductive tract and
pregnancy disorders, faces distinct challenges and microenvironments, such as the vaginal …

Ionizable lipid nanoparticles (LNPs) have gained attention as mRNA delivery platforms for
vaccination against COVID-19 and for protein replacement therapies. LNPs enhance mRNA …

There is still unmet demand for effective, safe, and patient-friendly anti-thrombotics to treat
deep vein thrombosis (DVT) during pregnancy. Here we first engineer a bioactive …

Nanotechnology holds immense promise in revolutionising healthcare, offering
unprecedented opportunities in diagnostics, drug delivery, cancer therapy, and combating …

The placenta is a transient organ that forms during pregnancy and acts as a biological
barrier, mediating exchange between maternal and fetal circulation. Placental disorders …